TABLE 3.

Predictive associations between HDL-C percent changes at 1 month and 3 months and clinical and brain imaging outcome measures

Clinical/MRI Variablea	ΔHDL-C% 1 Monthb			ΔHDL-C% 3 Monthsb
	Slope	P	q	Slope	P	q
PBVC	−2.55	1.2 × 10−8	1.2 × 10−7	−1.90	4.9 × 10−8	4.9 × 10−7
PGMVC	−1.67	0.004	0.02	−1.70	1.4 × 10−4	4.7 × 10−4
PLVVC	3.39	0.16	0.23	5.5	0.005	0.013
New T2 lesions	−3.13	0.16	0.27	−0.644	0.71	0.71
New/enlarging T2 lesions	−6.39	0.035	0.07	−1.45	0.54	0.68
CEL	1.12	0.47	0.52	0.687	0.56	0.62
EDSS	−0.01	0.96	0.96	0.324	0.054	0.077
Cumulative relapses	0.187	0.42	0.52	0.391	0.024	0.04

Slope, P value, and q value (false discovery rate) are provided.

^aIn MS decreases in normalized brain volume, decreases in gray matter volume, increases in lateral ventricle volume, increases in the number of T2 lesions, increases in CEL, increases in EDSS, and increases in cumulative relapses are adverse MRI/clinical outcomes.

^bΔHDL-C% at 1 month and ΔHDL-C% at 3 months are positive when HDL levels are increased relative to baseline, zero when HDL is unchanged relative to baseline, and negative when HDL is decreased relative to baseline.